Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The Trump administration is proposing to abolish NIAID's Division of Clinical Research, with Democrats alleging the freed-up funds are being funneled to the Pentagon via an interagency deal that wasn't shared with Congress. Infectious disease specialists and lawmakers are raising serious concerns, warning the move threatens research on HIV, influenza, TB, and more. The public comment window is just five days.
The Trump administration has proposed eliminating the National Institute of Allergy and Infectious Diseases' (NIAID) Division of Clinical Research (DCR) — a unit that oversees intramural clinical research, regulatory compliance, and global research capacity. The two-page Federal Register notice, signed by NIAID Acting Director John Powers III, MD, offers scant details and allows only a five-day public comment period (Sept. 14–18), drawing sharp criticism from researchers and lawmakers alike.
Democrats in Congress allege the savings from dismantling the DCR are being quietly redirected to the Pentagon through an interagency agreement that was never proactively shared with Congress. Sen. Patty Murray (D-Wash.) called it an attempt to "rob NIH of billions of dollars" earmarked for medical research, while Rep. Rosa DeLauro (D-Conn.) warned it would gut funding for research on HIV, influenza, and tuberculosis.
Key Takeaways:
Why it matters: Eliminating the DCR could have sweeping consequences for the U.S.'s ability to respond to infectious disease threats — and the limited transparency and compressed timeline surrounding the proposal have left clinicians, researchers, and Congress largely in the dark.
